Steven Gange
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Teleflex LLC at 50.2% of the total. Reporting peaked in 2020 at $507,792 and has fallen 99.6% since, to $2,202 in 2024. Among urology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,699 payments — averaging $910.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$777K
- Neotract Inc.$757K
- Coloplast$3K
- Angiodynamics, Inc.$3K
- Uromedica, Incorporated$2K
- Procept Biorobotics Corporation$1K
- plus $3K from 24 others
Across 4 payments — averaging $2549.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neotract Inc.$5K
- Boston Scientific$5K
What the payments were for
- Consulting fees$480,97831%
- Speaking & faculty fees$892,44558%
- Travel & lodging$135,8839%
- Food & beverage$35,6342%
- Education$2,0000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 870 | $776,900 |
| Neotract Inc. | 722 | $756,990 |
| Coloplast | 5 | $3,313 |
| Angiodynamics, Inc. | 13 | $3,009 |
| Uromedica, Incorporated | 6 | $2,065 |
| Procept Biorobotics Corporation | 5 | $1,489 |
| Valencia Technologies Corporation | 1 | $686 |
| Profound Medical Corp. | 4 | $419 |
| AbbVie(2 entities) | 17 | $402 |
| Astellas Pharma US Inc | 9 | $325 |
| SRS Medical Systems, Inc. | 2 | $317 |
| Ferring Pharmaceuticals Inc. | 2 | $120 |
| Pfizer | 6 | $111 |
| Endo Pharmaceuticals Inc. | 7 | $99 |
| Palette Life Sciences, Inc. | 1 | $90 |
| Travere Therapeutics, Inc. | 4 | $88 |
| Olympus America Inc. | 1 | $77 |
| Myovant Sciences Inc. | 4 | $70 |
| Amgen | 3 | $67 |
| Sumitomo Pharma America, Inc. | 3 | $61 |
| Antares Pharma, Inc. | 4 | $54 |
| Tolmar Pharmaceuticals, Inc. | 1 | $38 |
| Ambu Inc. | 2 | $37 |
| Dendreon Pharmaceuticals LLC | 1 | $21 |
| Merck | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Blue Earth Diagnostics | 1 | $16 |
| Bayer | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$915,742
- UroLift System$584,575
- UroLift ATC System$3,427
- ALTIS$3,230
- Nanoknife$2,719
- ProACT$1,954
- AquaBeam Robotic System$1,390
- UroLift 2 System$875
- eCoin Device Kit$686
- Tulsa-Pro$376
- UroCuff$222
- NOCDURNA$112
How this compares
$1,546,940 in reported general payments places this provider in the 95th percentile of 96 urology providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Alfuzosin Hcl ErAlfuzosin Hcl | 11 | $237 |
Paid to pharmacies, not to this prescriber.
Other urology in Slc
- Peter FisherSlc$8K
- Scott HopkinsSlc$4K
- William BrantSalt Lake City$290K
- Roscoe NelsonAmerican Fork$152K
- Nathan PursifullAmerican Fork$86K
- Benjamin McCormickSalt Lake City$67K
- Richard MaternSalt Lake City$58K
- Akhil SajiSalt Lake City$49K
- Jeffrey SparenborgProvo$37K
- Daniel SimonRiverton$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.